
    
      Participants will be enrolled in two steps (Cohort 1 and Cohort 2). Step one will enroll
      Cohort 1 made of 40 participants randomized in two groups with a 1:1 ratio.

      After review of the local and systemic adverse events occurring during the 7 Days following
      the first dose administered in these subjects, 2nd vaccination of Cohort 1 participants will
      resume and enrollment of the participants of Cohort number 2 will start. Step two will enroll
      Cohort 2 made of subjects randomized in two groups with a 1:1 ratio.

      A sub-study Group C will be enrolled and will receive the vaccine by intramuscular route.
    
  